Skip to main content

Table 2 Preclinical antibody–drug conjugates active in animal models of lymphoma

From: Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress

Agent Target Linker Payload Indication
huB4-DGN462 CD19 Sulfo-SPDB DGN462 B cell lymphoma [150]
RC58-based ADC CD19 Maleimide-PEG-based linkers / B cell lymphoma [151]
Anti-CD30-LDM CD30 Non-cleavable linker LDM HL and ALCL [110]
CD38-077 CD38 Non-polyethylene glycol linker Duostatin 5.2 Burkitt's lymphoma and MM [152]
BAY-943 (IL3RA-ADC) CD123 Protease-cleavable linker KSP inhibitor AML and HL [153]
BAY 924 CD185 / KSP inhibitor B cell lymphoma [154]
MEN1309/OBT076 CD205 SPDB DM4 B cell lymphoma [155]
IMMU-140 HLA-DR Cleavable linker SN-38 HL, NHL and CLL [156]
  1. ALCL, anaplastic large cell lymphoma; HL, Hodgkin lymphoma; MM, multiple myeloma; AML, acute myeloid leukemia; NHL, non-Hodgkin lymphoma; CLL, chronic lymphocytic leukemia; KSP, kinesin spindle protein